Literature DB >> 8051432

Disappearance rate of serum calcitonin after total thyroidectomy for medullary thyroid carcinoma.

L Fugazzola1, A Pinchera, F Luchetti, P Iacconi, P Miccoli, C Romei, M Puccini, F Pacini.   

Abstract

We studied the half-life of serum calcitonin (CT) in patients subjected to total thyroidectomy for medullary thyroid carcinoma (MTC). One patient showed a rapid serum CT component with a half-life of 3 hours and a slow component with a half-life of 30 hours; in another case only the 30-hour component was found. By chromatography of tumor extracts, we found that all the immunoreactive CT had a molecular weight of 3,600. After surgery, normalization of serum CT was achieved within 15 days in 4 patients, at 3 months and at 6 months in 2 other patients, while 1 patient never normalized. Normalization of serum CT after surgery is not an index of definitive cure in MTC, as demonstrated by one patient who relapsed 3 months after normalization of serum CT. However, as a general rule, patients who reach undetectable serum CT levels soon after surgery, are those having the best prognosis.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8051432     DOI: 10.1177/172460089400900104

Source DB:  PubMed          Journal:  Int J Biol Markers        ISSN: 0393-6155            Impact factor:   3.248


  9 in total

1.  Procalcitonin: a marker for the diagnosis and follow-up of patients with medullary thyroid carcinoma.

Authors:  Alicia Algeciras-Schimnich; Carol M Preissner; J Paul Theobald; Mary S Finseth; Stefan K G Grebe
Journal:  J Clin Endocrinol Metab       Date:  2008-12-16       Impact factor: 5.958

Review 2.  Advances in the follow-up of differentiated or medullary thyroid cancer.

Authors:  Rossella Elisei; Aldo Pinchera
Journal:  Nat Rev Endocrinol       Date:  2012-04-03       Impact factor: 43.330

3.  Serum calcitonin nadirs to undetectable levels within 1 month of curative surgery in medullary thyroid cancer.

Authors:  Fernanda Andrade; Geneviève Rondeau; Laura Boucai; Rebecca Zeuren; Ashok R Shaha; Ian Ganly; Fernanda Vaisman; Rossana Corbo; Michael Tuttle
Journal:  Arch Endocrinol Metab       Date:  2019-03-21       Impact factor: 2.309

Review 4.  Medical management of metastatic medullary thyroid cancer.

Authors:  Jessica E Maxwell; Scott K Sherman; Thomas M O'Dorisio; James R Howe
Journal:  Cancer       Date:  2014-06-18       Impact factor: 6.860

Review 5.  Evidence-based approach to the management of sporadic medullary thyroid carcinoma.

Authors:  Jeffrey F Moley; Elizabeth A Fialkowski
Journal:  World J Surg       Date:  2007-05       Impact factor: 3.352

Review 6.  Biochemical Testing in Thyroid Disorders.

Authors:  Nazanene H Esfandiari; Maria Papaleontiou
Journal:  Endocrinol Metab Clin North Am       Date:  2017-06-08       Impact factor: 4.741

7.  Correlation between Calcitonin Levels and [(18)F]FDG-PET/CT in the Detection of Recurrence in Patients with Sporadic and Hereditary Medullary Thyroid Cancer.

Authors:  Evangelia Skoura; Ioannis E Datseris; Phivi Rondogianni; Stylianos Tsagarakis; Marinella Tzanela; Maria Skilakaki; Dimitrios Exarhos; Maria Alevizaki
Journal:  ISRN Endocrinol       Date:  2012-05-10

Review 8.  Medullary thyroid cancer: medical management and follow-up.

Authors:  Amber Traugott; Jeffrey F Moley
Journal:  Curr Treat Options Oncol       Date:  2005-07

9.  Procalcitonin as Marker of Recurrent Medullary Thyroid Carcinoma: A Systematic Review and Meta-Analysis.

Authors:  Pierpaolo Trimboli; Luca Giovanella
Journal:  Endocrinol Metab (Seoul)       Date:  2018-06
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.